Show simple item record

dc.contributor.authorLewis, TS
dc.contributor.authorKennedy, Jason
dc.contributor.authorPrice, Gareth J
dc.contributor.authorMee, Thomas
dc.contributor.authorWoolf, David K
dc.contributor.authorBayman, Neil A
dc.contributor.authorChan, Clara
dc.contributor.authorCoote, Joanna H
dc.contributor.authorFaivre-Finn, Corinne
dc.contributor.authorHarris, Maggie A
dc.contributor.authorHudson, Andrew M
dc.contributor.authorPemberton, Laura S
dc.contributor.authorSalem, Ahmed
dc.contributor.authorSheikh, Hamid Y
dc.contributor.authorMistry, HB
dc.contributor.authorCobben, David
dc.date.accessioned2020-08-10T08:09:22Z
dc.date.available2020-08-10T08:09:22Z
dc.date.issued2020en
dc.identifier.citationLewis TS, Kennedy JA, Price GJ, Mee T, Woolf DK, Bayman NA, et al. Palliative Lung Radiotherapy: Higher Dose Leads to Improved Survival? Clin Oncol (R Coll Radiol). 2020.en
dc.identifier.pmid32600918en
dc.identifier.doi10.1016/j.clon.2020.05.003en
dc.identifier.urihttp://hdl.handle.net/10541/623107
dc.description.abstractAims: Choosing the optimal palliative lung radiotherapy regimen is challenging. Guidance from The Royal College of Radiologists recommends treatment stratification based on performance status, but evidence suggests that higher radiotherapy doses may be associated with survival benefits. The aim of this study was to investigate the effects of fractionation regimen and additional factors on the survival of palliative lung cancer radiotherapy patients. Materials and methods: A retrospective univariable (n = 925) and multivariable (n = 422) survival analysis of the prognostic significance of baseline patient characteristics and treatment prescription was carried out on patients with non-small cell and small cell lung cancer treated with palliative lung radiotherapy. The covariates investigated included: gender, age, performance status, histology, comorbidities, stage, tumour location, tumour side, smoking status, pack year history, primary radiotherapy technique and fractionation scheme. The overall mortality rate at 30 and 90 days of treatment was calculated. Results: Univariable analysis revealed that performance status (P < 0.001), fractionation scheme (P < 0.001), comorbidities (P = 0.02), small cell histology (P = 0.02), 'lifelong never' smoking status (P = 0.01) and gender (P = 0.06) were associated with survival. Upon multivariable analysis, only better performance status (P = 0.01) and increased dose/fractionation regimens of up to 30 Gy/10 fractions (P < 0.001) were associated with increased survival. Eighty-five (9.2%) and 316 patients (34%) died within 30 and 90 days of treatment, respectively. Conclusion: In this retrospective single-centre analysis of palliative lung radiotherapy, increased total dose (up to and including 30 Gy/10 fractions) was associated with better survival regardless of performance status. Keywords: Lung cancer; outcomes research; palliative care; radiotherapy.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.clon.2020.05.003en
dc.titlePalliative lung radiotherapy: higher dose leads to improved survival?en
dc.typeArticleen
dc.contributor.departmentDepartment of Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, UK.en
dc.identifier.journalClinical Oncologyen
dc.description.noteen]
refterms.dateFOA2020-08-12T12:12:57Z


Files in this item

Thumbnail
Name:
Clinonc.pdf
Size:
1.056Mb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record